1)Oya M, Asakura H, Mizuno R, et al:Repeated regression of pulmonary metastasis from renal cell carcinoma after treatment using different interferon-alpha preparations. Biomed Res 26:135-137, 2005
2)堀口明男,内田 厚:二種の天然型インターフェロンαに対して異なる反応を呈した転移性腎細胞癌の1例.日泌尿会誌 95:50-53,2004
3)加藤祐司,佐賀祐司,堀 淳一,他:サイトカインの変更により異なる反応を呈した進行性腎細胞癌の1例.日泌尿会誌 97:598-601,2006
4)Foster GR, Rodrigues O, Ghouze F, et al:Different relative activities of human cell-derived interferon-α subtypes:IFN-α8 has very high antiviral potency. J Interferon Cytokine Res 16:1027-1033, 1996
. J Interferon Cytokine Res 21:1129-1136, 2001
6)Yamaoka T, Kojima S, Ichi S, et al:Biologic and binding activities of IFN-alpha subtypes in ACHN human renal cell carcinoma cells and Daudi Burkitt's lymphoma cells. J Interferon Cytokine Res 19:1343-1349, 1999
7)Itri LM, Campion M, Dennin RA, et al:Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection. Cancer 59:668-674, 1987
8)Steis RG, Smith JWⅡ, Urba WJ, et al:Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318:1409-1413, 1988
9)Gotoh A, Hara I, Fujisawa M, et al:Pharmacokinetics of natural human IFN-α in hemodialysis patients. J Interferon Cytokine Res 19:1117-1123, 1999
10)石井泰憲,金子昌司,立川隆光,他:透析患者の腎細胞癌に対するインターフェロン療法.透析会誌 31:1379-1381,1998